Abstract
Tuberculosis is a major infectious disease worldwide, but currently available diagnostics have suboptimal accuracy, particularly in patients unable to expectorate, and are often unavailable at the point-of-care in resource-limited settings. Test/treatment decision are, therefore, often made on clinical grounds. We hypothesized that contextual factors beyond disease probability may influence clinical decisions about when to test and when to treat for tuberculosis. This umbrella review aimed to identify such factors, and to develop a framework for uncertainty in tuberculosis clinical decision-making. Systematic reviews were searched in seven databases (MEDLINE, CINAHL Complete, Embase, Scopus, Cochrane, PROSPERO, Epistemonikos) using predetermined search criteria. Findings were classified as barriers and facilitators for testing or treatment decisions, and thematically analysed based on a multi-level model of uncertainty in health care. We included 27 reviews. Study designs and primary aims were heterogeneous, with seven meta-analyses and three qualitative evidence syntheses. Facilitators for decisions to test included providers’ advanced professional qualification and confidence in tests results, availability of automated diagnostics with quick turnaround times. Common barriers for requesting a diagnostic test included: poor provider tuberculosis knowledge, fear of acquiring tuberculosis through respiratory sampling, scarcity of healthcare resources, and complexity of specimen collection. Facilitators for empiric treatment included patients’ young age, severe sickness, and test inaccessibility. Main barriers to treatment included communication obstacles, providers’ high confidence in negative test results (irrespective of negative predictive value). Multiple sources of uncertainty were identified at the patient, provider, diagnostic test, and healthcare system levels. Complex determinants of uncertainty influenced decision-making. This could result in delayed or missed diagnosis and treatment opportunities. It is important to understand the variability associated with patient-provider clinical encounters and healthcare settings, clinicians’ attitudes, and experiences, as well as diagnostic test characteristics, to improve clinical practices, and allow an impactful introduction of novel diagnostics.
Funder
National Institute Of Allergy And Infectious Diseases of the National Institutes of Health
Publisher
Public Library of Science (PLoS)
Reference85 articles.
1. World Health Organization. WHO Global Tuberculosis Report 2023. Geneva; 2023. Available from: https://www.who.int/publications/i/item/9789240083851
2. High-quality health systems in the Sustainable Development Goals era: time for a revolution;ME Kruk;Lancet Glob Heal,2018
3. Quality: The missing ingredient in TB care and control;M Pai;J Clin Tuberc Other Mycobact Dis,2019
4. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis ‐ Rapid diagnostics for tuberculosis detection 2021 update [Internet]. 2021 [cited 2022 Feb 1]. Available from: https://www.who.int/publications/i/item/9789240029415
5. Market penetration of Xpert MTB/RIF in high tuberculosis burden countries: A trend analysis from 2014–2016;D Cazabon;Gates Open Res,2018
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献